Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

China NT Pharma Group Co Ltd Comments On H1 2013 Earnings Guidance


Wednesday, 31 Jul 2013 10:02am EDT 

China NT Pharma Group Co Ltd announced that it will likely record a loss for the first half of 2013. The loss is mainly attributed to the Company's business restructuring measures introduced in 2012 which involved the exiting from its vaccine and pharmaceutical supply chain business, the downsizing of its vaccine sales and promotion team as well as the termination of its over-the-counter promotion business and several dermatological products. As a result, the Company may incur further impairment charges for account receivables and inventories in relation to the terminated businesses, which will likely lead to a loss for the first half of 2013. 

Company Quote

1.34
0.02 +1.52%
3:59am EDT